Literature DB >> 9717810

Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells.

P L Lollini1, L Landuzzi, F Frabetti, I Rossi, G Nicoletti, K Scotlandi, M Serra, N Baldini, C De Giovanni, P Nanni.   

Abstract

CD40, a membrane glycoprotein of the tumor necrosis factor receptor family, is expressed by several tumor types, including B-cell lymphomas, carcinomas, and melanoma, but little is known concerning its expression by sarcoma. We used flow cytometry to analyze the expression of CD40 in human cell lines derived from 12 osteosarcomas, 6 Ewing's sarcomas, and 5 rhabdomyosarcomas. Detectable CD40 levels ranging from low to very high were found in one-third of osteosarcomas, whereas five of six Ewing's sarcomas expressed intermediate levels of CD40; all rhabdomyosarcomas were CD40-negative. At the tissue level, two of eight primary high-grade osteosarcomas showed CD40-positive immunostaining. Osteosarcoma cells and Ewing's sarcoma cells expressing CD40 were treated with recombinant soluble CD40 ligand to analyze CD40 function. Treatment with soluble CD40 ligand increased the level of apoptotic cells and stimulated the transcription of matrix metalloproteinase 9 gene, enhancing matrix metalloproteinase 9 enzyme secretion. The results indicate that in human osteosarcoma and Ewing's sarcoma, CD40 is a functional receptor whose engagement can have opposite effects on tumor cell survival and malignancy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9717810

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  4 in total

1.  Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.

Authors:  Kevin J Curran; Beatrijs A Seinstra; Yan Nikhamin; Raymond Yeh; Yelena Usachenko; Dayenne G van Leeuwen; Terence Purdon; Hollie J Pegram; Renier J Brentjens
Journal:  Mol Ther       Date:  2015-01-13       Impact factor: 11.454

2.  The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit.

Authors:  L Landuzzi; C De Giovanni; G Nicoletti; I Rossi; C Ricci; A Astolfi; L Scopece; K Scotlandi; M Serra; G P Bagnara; P Nanni; P L Lollini
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  Serum concentrations of sCD30 and sCD40L in patients with malignant bone tumours.

Authors:  Gerold Holzer; Thomas Pfandlsteiner; Harald Blahovec; Klemens Trieb; Rainer Kotz
Journal:  Wien Med Wochenschr       Date:  2003

4.  High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance.

Authors:  Laura Caggiari; Massimo Guidoboni; Emanuela Vaccher; Luigi Barzan; Giovanni Franchin; Annunziata Gloghini; Debora Martorelli; Paola Zancai; Maria Teresa Bortolin; Mario Mazzucato; Diego Serraino; Antonino Carbone; Paolo De Paoli; Riccardo Dolcetti
Journal:  Infect Agent Cancer       Date:  2007-03-01       Impact factor: 2.965

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.